Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Gynecol Endocrinol ; 17(2): 159-68, 2003 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-12737677

RESUMO

The aim of the present study was to evaluate the effect of long-term (12 months) administration of raloxifene hydrochloride (60 mg/day) on the steroid production of the adrenal cortex and on the hypothalamic-pituitary-adrenal axis in postmenopausal women. We performed a basal evaluation, a corticotropin releasing factor (CRF) (100 microg i.v. bolus) test and a dexamethasone (DXM) (0.25 mg) suppression-adrenocorticotropic hormone (ACTH) (10 microg i.v. bolus) stimulation test in 11 postmenopausal women, before and after 3, 6 and 12 months of raloxifene treatment. Raloxifene administration significantly modified circulating levels of adrenal steroids, decreasing cortisol (-24%), dehydroepiandrosterone (DHEA) (-36%), and its sulfate (DHEAS) (-41%), and androstenedione (-29%), and increasing circulating allopregnanolone (+39%) levels. Progesterone and 17OH-progesterone levels remained unmodified, while estradiol and estrone levels showed a significant decrease (-51% for estradiol and -61% for estrone). We also observed an increase in circulating ACTH (+58%) and beta-endorphin (+120%). No modifications in the hormonal responses to CRF were observed during the treatment. DXM significantly suppressed circulating steroids at any time with a lower suppression of cortisol from the third month and a higher suppression of DHEA at 12 months. ACTH administration was associated with a significantly blunted cortisol response from the sixth month and a significantly increased response of allopregnanolone from the third month. The present data exclude a raloxifene effect on pituitary sensitivity to CRF and demonstrate a reduced adrenal sensitivity to ACTH, sustained by the opposite changes in basal cortisol and Delta5 androgens, which were reduced, and in ACTH and beta-endorphin, which were increased, as well by the reduced response of cortisol to the direct ACTH stimulus. The reduction of circulating cortisol levels and cortisol response to the ACTH challenge suggests that raloxifene protects against the neurotoxic effects of endogenous glucocorticoids. Furthermore, the progressive increase in basal allopregnanolone and its increased response to ACTH indicate that chronic raloxifene administration exerts direct effects on the pattern of adrenal enzymes, leading to specific changes in the circulating levels of this anxiolytic progesterone metabolite. The important reduction in the circulating levels of estradiol and estrone under long-term raloxifene administration may represent a further mechanism by which this molecule may exert a protective effect against breast and endometrial malignancies.


Assuntos
Córtex Suprarrenal/efeitos dos fármacos , Córtex Suprarrenal/fisiologia , Cloridrato de Raloxifeno/administração & dosagem , Moduladores Seletivos de Receptor Estrogênico/administração & dosagem , Hormônio Adrenocorticotrópico/sangue , Androstenodiona/sangue , Índice de Massa Corporal , Hormônio Liberador da Corticotropina , Desidroepiandrosterona/sangue , Sulfato de Desidroepiandrosterona/sangue , Dexametasona , Estradiol/sangue , Estrona/sangue , Feminino , Glucocorticoides , Humanos , Hidrocortisona/sangue , Hipotálamo/efeitos dos fármacos , Hipotálamo/fisiologia , Pessoa de Meia-Idade , Hipófise/efeitos dos fármacos , Hipófise/fisiologia , Pós-Menopausa , Pregnanolona/sangue , beta-Endorfina/sangue
2.
Pharmacoeconomics ; 13(1 Pt 2): 135-46, 1998 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-10176148

RESUMO

This 9-month pragmatic study compared 2 therapeutic regimens in the management of osteoarthritis of the hip and knee. Patients received either diacerein 100 mg/day plus standard osteoarthritic therapy for 6 months, followed by a 3-month monitoring period without diacerein, or standard therapy alone for the entire 9-month period. A total of 207 patients with osteoarthritis of the knee and hip were enrolled. Improvements in Lequense's functional index and quality-of-life scores (revised Arthritis Impact Measurement Scales Health Status Questionnaire and Nottingham Health Profile), and decreases in nonsteroidal anti-inflammatory drug and analgesic consumption were significantly greater with diacerein plus standard therapy than with standard therapy alone. The overall assessment of therapy by patients was good or excellent for 60% of those who received diacerein plus standard therapy, compared with 26% who received standard therapy alone. Medical and paramedical procedures carried out in addition to those stipulated in the protocol (medical consultations, physiotherapy, nursing, etc.), osteoarthritis-related, were fewer and less costly in the diacerein plus standard therapy group than in the standard therapy group. The average outpatient cost (in 1995 French francs) of osteoarthritis treatment in the standard therapy group was FF2272 compared with FF2360 in the diacerein plus standard therapy group. The cost-effectiveness ratios per point scored on Lequesne's index were FF1893 for the standard therapy group and FF1072 for the diacerein plus standard therapy group, leading to a saving of 43% with diacerein plus standard therapy. The marginal cost (additional cost corresponding to the clinical benefit obtained by adding diacerein to standard treatment) was FF88 per point scored on Lequesne's index.


Assuntos
Antraquinonas/economia , Anti-Inflamatórios não Esteroides/economia , Osteoartrite/economia , Idoso , Antraquinonas/efeitos adversos , Antraquinonas/uso terapêutico , Anti-Inflamatórios não Esteroides/efeitos adversos , Anti-Inflamatórios não Esteroides/uso terapêutico , Análise Custo-Benefício , Diarreia/induzido quimicamente , Método Duplo-Cego , Feminino , França , Humanos , Masculino , Pessoa de Meia-Idade , Osteoartrite/tratamento farmacológico , Estudos Prospectivos , Qualidade de Vida
3.
Rev Rhum Ed Fr ; 60(6 Pt 2): 63S-67S, 1993 Jul.
Artigo em Francês | MEDLINE | ID: mdl-8118454

RESUMO

The purpose of this study was to quantify the social and financial burden imposed by osteoarthritis in France. Six million new diagnoses of osteoarthritis are reported each year in France. The number of physician visits for osteoarthritis totals 8.7 million per year, for a total cost of 950 million French francs (FF). The cost of drugs prescribed to treat osteoarthritis is 965 million FF. Total annual cost of laboratory tests, roentgenograms, and rehabilitation therapy is 330 million French francs per year. The annual number of hospital admissions for osteoarthritis is 93,000. Duration of the hospital stay ranges from 11 to 16 days according the site involved. Hospital costs (in public and private institutions) total 1.7 billion French francs per year. Total direct costs related to osteoarthritis are 4 billion French francs per year. Indirect costs are the costs related to days of work lost. Sick leave benefits total 556 million FF and the production costs for the national economy are estimated at 1.6 billion French francs per year. Direct costs (4 billion FF) and indirect costs (at least 600 million FF) related to osteoarthritis represent an enormous burden for the French economy and national health care system. Novel treatments capable of substantially decreasing these costs would be of great value.


Assuntos
Osteoartrite/economia , Absenteísmo , Tratamento Farmacológico/economia , França , Hospitalização/economia , Humanos , Osteoartrite/terapia , Fatores Socioeconômicos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA